Skip to main content

Table 2 Baseline characteristics of responders and nonresponders to insulin glargine 100 Units/mL at 24 weeks

From: Characteristics of insulin-Naïve people with type 2 diabetes who successfully respond to insulin glargine U100 after 24 weeks of treatment: a meta-analysis of individual participant data from 3 randomized clinical trials

  Responders at 24 weeks
(HbA1c < 7% or ≥ 1% reduction) n = 1188
Nonresponders at 24 Weeks
(HbA1c ≥ 7% and < 1% reduction)
n = 297
P value
Age, years 57.8 (9.9) 57.2 (10.1) 0.323
Age group    0.833
 < 65 years 893 (75.2) 225 (75.8)  
 ≥ 65 years 295 (24.8) 72 (24.2)
Gender    0.012
 Women 543 (45.7) 160 (53.9)  
 Men 645 (54.3) 137 (46.1)  
Duration of T2DM, years 10.3 (6.6) 9.7 (6.5) 0.159
Weight, kg 87.5 (19.7) 85.8 (21.6) 0.201
BMI, kg/m2 31.3 (5.70) 30.9 (5.70) 0.213
HbA1c, % 9.1 (1.2) 8.3 (0.9) < 0.001
HbA1c, mmol/mol 99 (13) 91 (10) < 0.001
FBG, mg/dL 186.7 (52.0) 158.5 (42.2) < 0.001
≥ 1 OAMs Targeting PPGa 1111 (93.5) 290 (97.6) 0.006
 SU, yes 1067 (89.8) 284 (95.6) 0.002
 2 OAMs 790 (66.5) 194 (65.3) 0.701
  MET/SU 614 (51.7) 167 (56.2)
 3 OAMs 389 (32.7) 100 (33.7) 0.761
  MET/SU/TZD 346 (29.1) 89 (30.0)
 4 OAMs 7 (0.6) 3 (1.0) 0.429
  1. Individual participant data were pooled from 3 randomized clinical trials [20,21,22] and are mean (SD) or n (%). Patients are those who were randomized to insulin glargine as the only insulin treatment and with no missing HbA1c values at 24 weeks. Two-sided P values were considered statistically significant if < 0.05 and were calculated by ANOVA model (response = subgroup) for continuous variables and by Pearson’s Chi-square or Fisher’s exact (for OAM data with less than 80% of cells with an expected value ≥5) test for categorical variables. Abbreviations: AGI alpha glucosidase inhibitor, BMI body mass index, DPP-IV dipeptidyl peptidase IV, FBG fasting blood glucose, HbA1c glycated hemoglobin, MEG meglitinides, MET metformin, OAM oral antihyperglycemic medication, PPG postprandial blood glucose, SD standard deviation, SU sulphonylurea, T2DM type 2 diabetes mellitus, TZD thiazolidinedione. aOAMs targeting postprandial glucose were SU, DPP-IV, AGI, and MEG